Creative image of embryonic stem cells

CAS 生命科学数据

开展全新的生命科学发现时，完整且关联的数据是成功的关键。 借助世界上最值得信赖、最可靠的科学信息来源 CAS 内容合集™，深入研究疾病、靶点和新型分子之间的关系。

联系我们

We hope you’ve been enjoying the preview of CAS life sciences content and capabilities in CAS SciFinder®, which will end on June 1, 2024. These capabilities and many more are now available through the CAS BioFinder Discovery PlatformTM, which includes CAS BioFinder™, our newest solution to serve drug discovery scientists.

CAS Life Science flag

The CAS BioFinder Discovery Platform offers seamless integration with the capabilities you’ve seen in CAS SciFinder, such as sequence searches and bioactivity tables linked to reference documents and assay details. In addition, CAS BioFinder features embedded analytical and predictive models to help you explore the predicted behavior of novel molecules. The full platform also includes CAS APIs to directly access our human-curated bioactivity and biomarker data.

With this new platform, you can dive deeper to answer key drug discovery questions with the trusted, harmonized, and connected CAS content you depend on combined with analytical and predictive models directly accessible from your search results.

  • What scaffolds and molecules are associated with my disease of interest?
  • What molecules are known or likely to interact with my target of interest?
  • What targets are known or likely to interact with my molecules of interest?
  • What biomarkers are relevant to my disease of interest?
Learn more about the new CAS BioFinder Discovery Platform

  • SAR, ADME data, toxicity values, and other bioactivity observations and pharmacological data facilitate the discovery of novel targets for therapeutic intervention.

  • Indexed nucleic acid and protein sequences provide a better understanding of how sequence changes affect biological functions.

  • Molecular biomarkers used in predictions, diagnoses, and prognoses reveal underlying causes and effects of a disease.

  • 代谢信号通路和相互作用可进一步推断和发现疾病、分子和药理反应之间的联系。

  • 抗体、抗体药物偶联物、抗体融合蛋白、嵌合抗原受体和相关工程蛋白可用于诊断、治疗或免疫适应症/应用。

  • 不同数据类型之间的联系揭示了可靠的关键关系。

“CAS 数据库具有前所未有的全面性。”

小型制药公司研发副总裁/总监

TVID：17E-012-6D1

关于生命科学数据的更多信息

Close up of invasive colon cancer cells

药物发现过程中序列分析的挑战与机遇

Jefferson Parker，博士 NullSet Informatics Solutions 的 Jefferson Parker 博士分享了序列分析的重要性、人工智能技术如何改进序列分析以及仍然存在的关键问题。